CD8A and prostate cancer: Nonetheless, early CD8+ T cell infiltration in PRAD and persistence of potential DCs in late-stage NEPC in this model suggest that deeper analysis may be informative in addressing the disappointing clinical results seen with conventional immune checkpoint blockade therapy in prostate cancer.